Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07532265) titled 'A Phase 2 Dose Ranging Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma' on April 8.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Kinaset Therapeutics Inc
Condition:
Severe Asthma
Intervention:
Drug: Frevecitinib
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: June 1, 2026
Target Sample Size: 512
Countries of Recruitment:
United Sta...